Pharmaceutical

ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy

The subanalyses recontextualised data from the PACMAN-AMI trial on the therapeutic role of Praluent (alirocumab) in coronary heart disease.

Sep 6, 2024 - 04:00
ESC 2024: New PACMAN-AMI trial analysis sheds insights on Praluent efficacy
The subanalyses recontextualised data from the PACMAN-AMI trial on the therapeutic role of Praluent (alirocumab) in coronary heart disease.
Read the original article

Tags:

Previous Article

ESC 2024: Insights into RNA as therapeutic target and tool

Next Article

Lilly partners with Haya for lncRNA obesity target deal worth $1bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AGC Biologics and the Jikei University partner for IPF project

AGC Biologics and the Jikei University partner for IPF ...

Apr 4, 2023

STAT+: Medicare’s advisory committee isn’t sold on big pay raises for doctors

STAT+: Medicare’s advisory committee isn’t sold on big ...

Dec 9, 2023

‘Shocking’ heat waves persist through August as federal officials warn of far-ranging health risks

‘Shocking’ heat waves persist through August as federal...

Aug 3, 2023